A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 222 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Research with Integrity – integrating training into research culture January 24, 2023 What Are Social Determinants of Health and How Do They Affect... July 22, 2021 4 Ways to Manage Setbacks in Your Cancer Recovery: A Young... April 11, 2023 Foodie Friday: Pumpkin EVERYTHING! October 8, 2021 Load more HOT NEWS Teen With Terminal Cancer Gives Make-A-Wish Gift To Other Kids In... 2020 National Cancer Opinion Survey: Cancer Screening and Mental Health During... Only a Quarter of Phase III Studies Demonstrated Improved QoL in... New independent tobacco review sets roadmap for a smokefree England for...
